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ABSTRACT 8 
BACKGROUND  9 
Despite progress in understanding the genetics of rare epilepsies, the more common 10 
epilepsies have proven less tractable to traditional gene-discovery analyses. We aimed to 11 
assess the contribution of ultra-rare genetic variation to the common epilepsies. 12 
METHODS 13 
We did a case-control sequencing study using the exome sequence data from unrelated 14 
individuals clinically evaluated for one of the two most common epilepsy syndromes: 15 
familial genetic generalized epilepsy (GGE) or familial sporadic non-acquired focal epilepsy 16 
(NAFE). Individuals were recruited between Nov 26, 2007 and Aug 2, 2013 through the 17 
multicentre Epilepsy Phenome/Genome Project and Epi4K collaborations, and were 18 
sequenced at the Institute for Genomic Medicine, Columbia University (New York City, 19 
USA) between Feb 6, 2013 and Aug 18, 2015. To identify epilepsy risk signals, we tested all 20 
protein-coding genes for an excess of ultrarare genetic variation among the cases compared to 21 
unrelated individuals of European ancestry selected for control purposes through unrelated 22 
studies.  23 
FINDINGS 24 
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We separately compared the sequence data from 640 individuals with familial GGE and 525 25 
individuals with familial NAFE to the same group of 3,877 controls, and found significant 26 
excess of ultra-rare deleterious variation in genes established as causative for dominant 27 
epilepsy disorders (familial GGE: OR 2.3 [95% CI 1.7–3.2]; p=9.1x10-8) (familial NAFE: 28 
OR 3.6 [95% CI 2.7–4.9]; p=1.1x10-17). Comparing an additional collection of 662 29 
individuals with sporadic NAFE to controls did not identify study-wide significant signals. 30 
For the familial NAFE cases, we found that five previously known epilepsy genes ranked as 31 
the top five genes enriched for ultra-rare deleterious variation. After accounting for the 32 
control carrier rate we estimate that these five genes contribute to the risk of epilepsy in 33 
approximately 8% of familial NAFE cases. Our analyses showed that no individual gene was 34 
significantly associated with epilepsy; however, known epilepsy genes achieved lower p-35 
values relative to the rest of the protein-coding genes (p=5.8x10
-8
). 36 
INTERPRETATION 37 
We identified excess ultra-rare variation in known epilepsy genes, which establishes a clear 38 
connection between the genetics of common and rare severe epilepsies, and shows that the 39 
variants responsible for the observed epilepsy risk signal are exceptionally rare in the general 40 
population. Our results suggest that the emerging paradigm of targeting treatments to the 41 
genetic cause in rare devastating epilepsies may also extend to a proportion of common 42 
epilepsies. These findings might allow clinicians to broadly explain the aetiology of these 43 
syndromes to patients, and lay the foundation for possible precision treatments in the future. 44 
FUNDING 45 
National Institute of Neurological Disorders and Stroke (NINDS), Epilepsy-Research UK.  46 
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INTRODUCTION 47 
Next generation sequencing has proven successful in identifying genetic contributions to rare 48 
Mendelian disorders and cancers,
1, 2
 creating widespread optimism that treatments can be 49 
targeted to underlying causes of disease.
3
 Although epilepsy is a common complex disease, it 50 
is emerging as a group of disorders with precision medicine opportunities similar to those in 51 
rare Mendelian disorders and cancers.
4
 Unlike many common diseases, epilepsy genetics 52 
research is identifying not only the genes responsible, but also the genetic variants 53 
contributing to disease in individual patients. This is most apparent in the role of de novo 54 
mutations in the epileptic encephalopathies.
5, 6
 55 
Traditional heritability studies of the common epilepsies consistently show strong genetic 56 
effects in non-acquired focal epilepsy (NAFE) and in genetic generalized epilepsy (GGE), 57 
with both shared and distinct genetic contributions to these broadly defined epilepsies.
7, 8
 58 
Two important unresolved questions are the extent to which the genes responsible for rare 59 
severe epilepsies contribute to common epilepsies, and whether, as in the rare epilepsies, 60 
genetic risk arises primarily from ultra-rare variants of large effect including de novo 61 
mutations,
5, 6
 or from a constellation of common variants each conferring small or modest 62 
effect.
9-13
 63 
Exome sequencing of large case and control cohorts followed by genome-wide collapsing 64 
analyses provide a hypothesis-free approach to discovering novel disease genes and better 65 
understanding the overall contribution of ultra-rare genetic variation to disease.
14
 Here, we 66 
assess the contribution of ultra-rare genetic variation to common epilepsies while controlling 67 
for background variation in the general population.   68 
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METHODS 69 
Participants 70 
For this case-control study, participants with familial or sporadic NAFE or familial GGE 71 
were recruited between November 26, 2007 and August 2, 2013 through the international 72 
Epilepsy Phenome/Genome Project (EPGP) and Epi4K collaborations (appendix), as 73 
previously described.
15
 The case samples were sequenced between February 6, 2013 and 74 
August 18, 2015 by the Institute for Genomic Medicine, Columbia University (New York 75 
City, NY, USA). To be clinically classified as having NAFE, patients were required to have 76 
focal seizures and no evidence of an epileptogenic lesion on clinical imaging; however, 77 
hippocampal sclerosis was not considered an exclusion criterion. To be clinically classified as 78 
having GGE, patients were required to have a diagnosis of generalized epilepsy with absence, 79 
myoclonic or tonic-clonic seizures and generalized spike-and-wave on an EEG, and no or 80 
mild intellectual disability. All patients were clinically evaluated by their local clinician or 81 
the clinical team at recruiting centres. Individuals with unclassifiable epilepsy or classified as 82 
having both GGE and NAFE were excluded from the analyses. 83 
To be classified as a familial case, at least one reported relative (up to third degree) who had 84 
been diagnosed with epilepsy was required. The sporadic NAFE cohort included participants 85 
who self-reported no known epilepsy family history and were recruited from international 86 
hospital, outpatient, and epilepsy clinics (appendix).
15, 16
 Written informed consent was 87 
collected at the time of recruitment at each of the clinical sites. Patient collection and sharing 88 
of anonymised specimens for research was approved by site-specific Institutional Review 89 
Boards and ethic committees. 90 
 The control cohort comprised of unrelated individuals of European ancestry that had been 91 
selected for control purposes and sequenced through unrelated studies not focused on 92 
neurodevelopmental, neuropsychiatric or severe paediatric disease (appendix).  93 
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Procedures 94 
Sequencing was performed at the Institute for Genomic Medicine, Columbia University (New 95 
York City, NY, USA). Samples were exome sequenced using the Agilent All Exon (50MB or 96 
65MB; Agilent Technologies, Santa Clara, CA, USA) or the Nimblegen SeqCap EZ V2.0 or 97 
3.0 Exome Enrichment kit (Roche NimbleGen, Madison, WI, USA) or whole genome 98 
sequenced using HiSeq 2000 or 2500 (Illumina, San Diego, CA, USA) sequencers according 99 
to standard protocols.  100 
The sequence data from patients with epilepsy and controls were processed using the same 101 
Institute for Genomic Medicine bioinformatics pipeline (appendix). We focused on 18,668 102 
consensus coding sequence (CCDS; release 14) protein-coding genes. On average, at least 103 
10-fold coverage was achieved for 95.8% (familial GGE), 96.8% (familial NAFE), 97.1% 104 
(sporadic NAFE) and 95.6% (controls) of the 33.27 Mbps of the CCDS. For each protein-105 
coding site in the CCDS—inclusive of two base intronic extensions to accommodate 106 
canonical splice variants—we determined the percentage of cases and controls that had ≥10-107 
fold coverage at the site. To alleviate confounding due to differential coverage we used a site-108 
based pruning strategy similar to our previously described exon-pruning strategy.
17
 Individual 109 
CCDS sites were excluded from analysis if the absolute difference in the percentage of the 110 
cases compared to controls with adequate coverage of the site differed by greater than 5.19% 111 
(familial GGE vs. controls), 5.14% (familial NAFE vs. controls) and 6.39% (sporadic NAFE 112 
vs. controls) (appendix). Site-based pruning resulted in 8.9% (GGE), 8.3% (familial NAFE) 113 
and 8.3% (sporadic NAFE) of the CCDS bases excluded from the respective analyses to 114 
alleviate issues from differential coverage. Thus, all gene tests were performed on the pruned 115 
CCDS where cases and controls had similar opportunity to call gene variants (appendix). 116 
 117 
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STATISTICAL ANALYSIS 118 
To search for genes that confer risk for common epilepsy syndromes, we implemented a 119 
genic collapsing analysis,
17
 in which only a single affected individual (the index case) from 120 
each family was included. We applied standard procedures to address potential bias due to 121 
relatedness and population stratification (appendix). The analyses focused on CCDS protein-122 
coding sites with minimal variability in coverage between the case and control populations.  123 
As in our earlier work,
17
 the term “qualifying variants” has been adopted to refer to the subset 124 
of variation within the sequence data that meets specific criteria designed to enrich for 125 
pathogenic variants. We defined qualifying variants in four ways (Table 1). Our primary 126 
analysis focused on ultra-rare variants where a combination of internal (the test samples) and 127 
external data (the Exome Variant Server [EVS]
18
 and Exome Aggregate Consortium [ExAC; 128 
release 0.3]
19
). The test cohort was used to identify variants with a minor allele frequency 129 
(MAF) <0.05% among our combined case and control population being tested. The EVS and 130 
ExAC external databases were used to identify variants found among the test samples and 131 
absent (i.e., MAF=0%) among the two external reference control cohorts. The MAF was set 132 
to <0.05% in the combined case and control test collection to accommodate the possibility of 133 
multiple instances of a risk variant among cases. The two freely available EVS and ExAC 134 
external databases were solely used to support the rarity of the identified variants and did not 135 
contribute as control samples to the tests themselves. 136 
For the primary analysis, functional annotation focused on single nucleotide substitution and 137 
insertion or deletion variants annotated as having a loss-of-function, inframe insertion or 138 
deletion, or a “probably damaging” missense effect by PolyPhen-2 (HumDiv).20 Three 139 
secondary analyses were performed to evaluate the contribution to epilepsy risk from: rare 140 
loss-of-function variants with an internal and external population MAF up to 0.1%; rare non-141 
synonymous variation in the general population with an internal and external MAF up to 142 
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0.1%; and a presumed neutral model that imposed similar MAF thresholds as our primary 143 
analysis, but focused specifically on protein-coding variants predicted to have a synonymous 144 
effect. The purpose of the presumed neutral model was to further confirm that no cryptic 145 
factors might be increasing qualifying variant calling among one of the groups. 146 
For each of the four models, we tested the complete list of 18,668 CCDS genes. For each 147 
gene, an indicator variable (1/0 states) was assigned to each individual based on the presence 148 
of at least one qualifying variant in the gene (state 1) or no qualifying variants in that gene 149 
(state 0). We used a two-tailed Fisher’s exact test to identify genes where there was a 150 
significant enrichment of qualifying variants in the case or control group. To control for the 151 
type-I error rate within each epilepsy phenotype, we defined study-wide significance as 152 
p=8.9x10
-7
, correcting for 18,668 CCDS genes studied across three models (0.05/[3x18668]). 153 
We did not correct for the neutral control model. 154 
All collapsing analyses were performed using an in-house package, Analysis Tool for 155 
Annotated Variants (ATAV). Binomial tests were used to evaluate whether there was an 156 
enrichment of previously reported pathogenic variants among the case collection of 157 
qualifying variants. Hypergeometric tests were performed to assess whether among the 158 
collapsing analysis results the known epilepsy genes preferentially achieved lower p-values 159 
relative to the rest of the genome. Cochran-Mantel-Haenszel tests were adopted to combine 160 
the results of the gender stratified sex chromosome collapsing analyses.  161 
We also used the primary analysis results from each of the patient groups to assess 162 
enrichment among six biologically informed gene-sets that were chosen and described in our 163 
earlier studies of the epileptic encephalopathies,
5, 21
 including a list of 43 established 164 
dominant epilepsy genes (appendix).
3
 To account for background variation in gene-set tests 165 
we applied a logistic regression model (appendix). 166 
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To assess the contribution to epilepsy risk coming from variants with increasing minor allele 167 
frequencies (MAF), we developed a multivariable logistic regression model that focuses on 168 
the known epilepsy genes and relates disease risk to the presence of variants among 169 
increasing MAF bins (appendix).  170 
These additional binomial, hypergeometric, Cochran-Mantel-Haenszel, and logistic 171 
regression tests were completed using R package ‘stats’ version 3.2.2.  172 
ROLE OF THE FUNDING SOURCE 173 
The funders of the study had no role in study design, data collection, data analysis, data 174 
interpretation or writing of the report. The corresponding author had full access to the data in 175 
the study and had final responsibility for the decision to submit for publication. 176 
 177 
RESULTS 178 
We sequenced the exomes of 1,827 patients with epilepsy—640 unrelated individuals with a 179 
diagnosis of familial GGE and 525 unrelated individuals with a diagnosis of familial NAFE 180 
of European ancestry. We also sequenced an additional 662 individuals with sporadic NAFE. 181 
We compared these three groups of patients with epilepsy to 3,877 controls, who were 182 
unrelated individuals of European ancestry with no known epilepsy diagnosis.  183 
 184 
Among our familial GGE cohort, no individual gene achieved study-wide significant 185 
enrichment for qualifying variants (Figure 1, appendix). Of the total 76,313 qualifying 186 
variants in the GGE primary analysis, 15.0% were found among cases in the familial GGE 187 
cohort. We then found that among the 76,313 qualifying variants, four unique variants 188 
overlapped a codon previously reported to have a pathogenic-classified epilepsy variant 189 
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based on the disease-associated variant catalogues of ClinVar, the Online Mendelian 190 
Inheritance in Man (OMIM), or the Human Gene Mutation Database (HGMD). All four 191 
variants (two SCN1A, one GABRG2, and one SCN1B; appendix) were found among the 192 
familial GGE cohort, an improbable enrichment given the expected proportion of 15.0% 193 
(p=5.1x10
-4
, two-tailed exact binomial test). Through an evaluation of the scientific literature, 194 
these four cases were confirmed as unrelated to those families reported in the literature. 195 
 196 
While no single gene attained study-wide significance in the familial GGE analysis, three 197 
known epilepsy genes (KCNQ2, GABRG2, and SCN1A), were among the top ten case-198 
enriched genes in the primary analysis (Figure 1). A hypergeometric test was run at each of 199 
the gene ranks occupied by one of the 43 established epilepsy genes (appendix), and we 200 
found that the enrichment was greatest at rank 151 whereby seven of the 43 known epilepsy 201 
genes had been accounted for (hypergeometric p=5.8x10
-8
; appendix). 202 
 203 
 When we assessed enrichment among six biologically informed gene-sets, we found that the 204 
familial GGE cohort had a significant enrichment of ultra-rare functional variation among 43 205 
known dominant epilepsy genes (p=9.1x10
-8
, OR=2.3 [95% C.I. 1.7–3.2]; Table 2) and a 206 
subset of 33 genes known to contribute to epileptic encephalopathy (p=2.6x10
-7
, OR=2.6 207 
[95% C.I. 1.8–3.6]).3 We confirmed that the signal of enrichment for qualifying variants 208 
among known epilepsy genes was consistently greater than the control rate across groupings 209 
of the familial GGE cohort, reflecting the number of affected relatives (appendix). While they 210 
did not achieve study-wide significance (defined as p< 8.9x10
-7
), we also investigated 211 
qualifying variant enrichment among the fragile X mental retardation protein associated 212 
genes,
22
 the genes encoding the NMDA receptor (NMDAR), and neuronal activity-regulated 213 
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cytoskeleton-associated protein, postsynaptic signalling complexes,
23
 mouse seizure-214 
associated orthologs,
24
 and ion channel protein-coding genes
25
 (Table 2). None of these gene-215 
set tests reported enrichment of neutral variation.  216 
 217 
Among the primary analysis of our familial NAFE cohort (figure 2A), DEPDC5 achieved 218 
study-wide significance (OR 8.1 [95% C.I. 3.6–18.3], p=1.8x10-7). LGI1 did not achieve 219 
study-wide significance (OR 29.9 [95% C.I. 6.0–288.0], p=1.4x10-6). Established epilepsy 220 
genes PCDH19 (OR 22.4 [95% C.I. 4.0–226.4], p=6.4x10-5), SCN1A (OR 5.5 [95% C.I. 2.3–221 
12.9], p=9.0x10
-5
) and GRIN2A (OR 7.5 [95% C.I. 2.2–25.1], p=5.3x10-4) occupied the 3rd – 222 
5
th
 genome-wide ranks (appendix), but were not study-wide significant after correcting for 223 
the 56,004 tests (Bonferroni corrected p = 1). A hypergeometric test indicated that it was 224 
highly improbable for five of the 43 known dominant epilepsy genes to occupy the top five 225 
positions of the primary analysis by chance (p=5.7x10-14) (appendix).  226 
 227 
Of 74,272 qualifying variants identified in the primary analysis of 525 individuals with 228 
familial NAFE and 3,877 controls, 9,092 (12.2%) of these were found among the familial 229 
NAFE cases. Among the 74,272 qualifying variants, nine variants overlapped a codon of a 230 
ClinVar, OMIM, or HGMD literature-reported pathogenic variant in a confirmed unrelated 231 
family. All nine unique variants (three DEPDC5, three PCDH19, one CHRNB2, one GRIN2A 232 
and one LGI1 variant; appendix) were found among nine distinct NAFE cases of the 233 
combined 4,402 unrelated samples used in the familial NAFE collapsing analysis, despite the 234 
expected proportion being 12.2% (exact binomial test p=6.2x10
-9
). 235 
The known dominant epilepsy gene-set (OR=3.6 [95% CI 2.7–4.9], p=1.1x10-17) and the 236 
epileptic encephalopathy gene-set (OR=3.3 [95% CI 2.3–4.7], p=5.0x10-11) were study-wide 237 
significantly enriched for qualifying variants among the primary analysis of familial NAFE 238 
cases (Table 2). As observed in the familial GGE cases, the signal of enrichment for 239 
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qualifying variants among known epilepsy genes remained consistently greater than the 240 
control rate across groupings of the familial NAFE cohort stratified by the number of affected 241 
relatives (appendix). Presumably neutral variation was not significantly enriched among any 242 
gene-set. Under the loss-of-function model, DEPDC5 achieved study-wide significance 243 
(OR=53.07, [95% C.I. 12.1–481.3], p=9.6x10-12), with 14 (2.7%) of familial NAFE cases 244 
having a DEPDC5 loss-of-function variant compared to only two (0.05%) controls. Focusing 245 
solely on PolyPhen-2 ‘probably damaging’ missense DEPDC5 qualifying variants showed 246 
that they were non-significant for enrichment (3 [0.6%] of 525 cases vs. 12 [0.3%] of 247 
3877controls; OR=1.9 [95% C.I. 0.3–6.9], p=0.41; Figure 2B and appendix). Results from 248 
the list of 43 known dominant epilepsy genes that achieved an uncorrected p<0.05 in the 249 
primary or loss-of-function models are listed in the appendix.  250 
 251 
Sanger sequencing was used to validate a subset of qualifying variants found among 19 252 
established and 13 candidate epilepsy genes (appendix). Our rate of Sanger validation was 253 
97.0% (128/132) of the qualifying variants identified through the collapsing tests (appendix). 254 
When available, we also Sanger sequenced qualifying variants among affected first-degree 255 
relatives of index cases used in the collapsing analyses. We looked at six genes where we had 256 
enough affected first-degree relatives to be sufficiently powered to achieve an uncorrected 257 
p<0.05 from a test of preferential segregation (appendix). Comparing to the expected rate of 258 
50%, SCN1A (88.2% co-occurrence; p=1.2x10
-3
), DEPDC5 (100% co-occurrence; p=4.9x10
-
259 
4
) and GRIN2A (100% co-occurrence; p=7.8x10
-3
) had significant co-occurrence among 260 
affected first-degree family members, after correcting for the six studied genes (adjusted 261 
α=8.3x10-3; appendix).  262 
 263 
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To explore which variants, as a function of MAF, are most important to the observed risk 264 
signal we performed conditional analyses (appendix). These analyses show that among the 265 
observed epilepsy risk signal, beyond the ultra-rare qualifying variants (i.e., absent in EVS 266 
and ExAC) there is no significant contribution from variants with minor-allele frequencies up 267 
to 0.1% population MAF. This was true for both the familial GGE and familial NAFE 268 
populations (Figure 3; appendix).  269 
 270 
Comparing 662 sporadic NAFE cases to controls did not identify study-wide significant 271 
genes across any of the three models (appendix). Of the five previously described familial 272 
NAFE top ranked genes, we found that only LGI1 achieved an uncorrected p-value of less 273 
than 0.05, (OR 8.8 [95% C.I. 1.0–105.7], p=0.025). None of the tested gene-sets were 274 
significantly enriched with qualifying variants among sporadic NAFE cases (Table 2, Figure 275 
3). 276 
 277 
DISCUSSION 278 
In this study, we demonstrate the presence of clear genetic risk signal for common epilepsies 279 
across genes established as responsible for familial and rare severe epilepsies. In our analysis 280 
of a cohort of individuals with familial NAFE, we found that five established epilepsy genes 281 
(DEPDC5, LGI1, PCDH19, SCN1,A and GRIN2A) occupy the top five positions genome-282 
wide, and after correcting for background variation, the collection of these five genes 283 
contribute to approximately 8% of patients with familial NAFE. Sampling from a similarly 284 
sized familial GGE collection identified three established epilepsy genes (KCNQ2, SCN1A, 285 
and GABRG2) ranking among the top ten genes. Power estimates highlight the potential for 286 
new epilepsy gene discovery using this framework on larger sample sizes (appendix). Using 287 
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the example from LGI1, while we found only two qualifying variants among 3,877 controls 288 
(0.05%), identifying eight familial NAFE case carriers in the primary analysis (1.5% of the 289 
familial NAFE cohort) was still inadequate to achieve study-wide significance (p<8.9x10
-7
) 290 
for this known familial NAFE gene. Assuming the sampled rates for LGI1 case and control 291 
carriers remain the same, we estimate that LGI1 would achieve study-wide significance with 292 
the inclusion of approximately twice as many controls and 70 more unrelated familial NAFE 293 
cases. 294 
As in earlier studies, our data show that SCN1A contributes to risk in both the familial GGE 295 
and familial NAFE epilepsy cohorts
11
 and this enrichment is not explained by diagnoses of 296 
generalized epilepsy with febrile seizures plus (GEFS+). SLC9A2 was also among the top 20 297 
genes in both the familial NAFE and familial GGE cohort analyses; however, it did not reach 298 
study-wide significance.No clear risk signal for epilepsy was found among the sporadic 299 
NAFE cohort. This might be explained by the possibility that non-genetic (acquired) causes 300 
play a more important role among individuals with sporadic NAFE, leading to substantially 301 
reduced power but otherwise similar genetics. Other unexplored genetic contributions to the 302 
sporadic NAFE cohort include somatic mutations arising later in development, limited to the 303 
brain or at undetectable levels in blood-extracted DNA using conventional whole-exome 304 
sequencing.  305 
Among the most important findings in this work is our ability to identify clear risk signal in 306 
these data and subsequently show that the observed risk signal is concentrated among the 307 
rarest variants in the human population. In fact, among the 43 established dominant epilepsy 308 
genes we have shown that there is no evidence of risk contribution from variants observed at 309 
greater than 0.005% allelic frequency. This, however, does not preclude any other 310 
contributions to risk being present among currently unrecognized epilepsy risk genes. This 311 
work not only illustrates the value of large reference control variant databases,
19
 but provides 312 
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clinically relevant information concerning the frequency spectrum of risk variants for a 313 
common complex disease. 314 
A new paradigm is emerging for the treatment of rare devastating epilepsies, where 315 
treatments are being targeted to the precise genetic cause of disease.
3, 26-28
 For example, 316 
children with KCNT1 gain-of-function mutations have been treated with quinidine
27, 29
 while 317 
patients with GRIN2A gain-of-function mutations have been treated with memantine, a 318 
specific NMDA receptor blocker.
28, 30
 As this paradigm becomes more established, a critical 319 
question for the field is whether the approach will also apply to common epilepsies. If so, the 320 
field, which is currently accustomed to undertaking large randomised controlled trials in 321 
broad phenotypes, needs to rapidly develop a framework for classification based on ultra-rare 322 
variants in what is effectively a collection of rare genetic diseases. The work presented here 323 
demonstrates that many genes responsible for devastating rare and familial epilepsies also 324 
contribute to more common epilepsies, and it is still the ultra-rare variants that are relevant in 325 
those genes. This suggests that the emerging precision medicine paradigm of targeting 326 
treatments to the underlying causes of disease in the rarest epilepsies may also find 327 
application among the common epilepsies.   328 
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RESEARCH IN CONTEXT 329 
Evidence before this study 330 
The genetic underpinnings of the common epilepsies are largely unknown, especially the 331 
relative contributions of common variants of small effect size versus rare variants of large 332 
effect, where opportunities for novel therapeutic strategies may be greater.  We searched 333 
PubMed for the terms “exome sequencing” and “common epilepsy” for reports published 334 
before June 28, 2016, with no language restrictions. There were no reports of exome 335 
sequencing of large case collections of common complex epilepsies. Although exome 336 
sequencing studies have been successful in implicating numerous genes and finding the 337 
relevant mutations for individuals with rare severe paediatric epilepsies, including epileptic 338 
encephalopathies, estimating the risk contribution from the ultra-rare protein-coding variants 339 
has been less clear for many of the common epilepsy syndromes. 340 
Added value of this study 341 
We used whole-exome sequencing on a large collection of two common epilepsy syndromes, 342 
genetic generalized epilepsy (GGE) and non-acquired focal epilepsy (NAFE), to search for an 343 
excess of ultra-rare deleterious qualifying variants, and compared the qualifying variant rates 344 
found among cases to background rates estimated from sequenced controls. Among familial 345 
index cases sampled from the common epilepsies, we found a significant excess of ultra-rare 346 
deleterious variation within known epileptic encephalopathy genes. We also demonstrate that 347 
the epilepsy risk signal observed in the known epilepsy genes is accounted for by the ultra-348 
rare class of variants that are absent among large reference control cohorts, such as ExAC and 349 
EVS. Variants in known epilepsy genes that were predicted to be deleterious, but found at 350 
very low frequencies among the population reference cohorts, showed no evidence of 351 
contribution to the observed epilepsy risk signal.  352 
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Implications of all the available evidence 353 
The present findings provide three key conclusions important to our understanding of the 354 
common epilepsies. First, identifying significant enrichment of ultra-rare deleterious variants 355 
among established epilepsy genes illustrates that there are genuine signals to be found using 356 
the analysis framework presented here. Secondly, we showed that the precision medicine 357 
framework that is emerging for rare epilepsies can be expected to find applications among 358 
more common epilepsies. Finally, we showed that the risk signals among the common 359 
complex forms of epilepsy come from the rarest variants in the human population, providing 360 
the clearest insight currently available into the genetic variants underlying this common 361 
complex disorder. Further research is warranted to understand to what extent these findings 362 
can be applied to clinical practice. 363 
 364 
  365 
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Cohort Model 
Internal 
MAF(%) 
External 
MAF(%) 
Variant Effects 
# Genes with >0 
qualifying variant(s) 
CCDS represented 
in the tests (%) 
Familial 
GGE  
Primary^ 0.05% 0% 
LoF 
inframe insertions or deletions  
PolyPhen-2 (HumDiv) “probably” damaging 
15,515 
30.3Mbp (91.1%) 
LoF 0.1% 0.1% LoF 10,712 
Common 
(0.1% MAF) 
0.1% 0.1% 
LoF 
inframe insertions or deletions 
PolyPhen-2 (HumDiv) “probably” damaging 
17,118 
Presumed 
Neutral 
0.05% 0% Synonymous substitution 14,959 
Familial 
NAFE 
Primary^ 0.05% 0% 
LoF 
inframe insertions or deletions  
PolyPhen-2 (HumDiv) “probably” damaging 
15,438 
30.5Mbp (91.7%) 
LoF 0.1% 0.1% LoF 10,601 
Common 
(0.1% MAF) 
0.1% 0.1% 
LoF 
inframe insertions or deletions 
PolyPhen-2 (HumDiv) “probably” damaging 
17,089 
Presumed 0.05% 0% Synonymous substitution 14,871 
24 
 
Neutral 
Sporadic 
NAFE  
Primary^ 0.05% 0% 
LoF 
inframe insertions or deletions  
PolyPhen-2 (HumDiv) “probably” damaging 
15,507 
30.5Mbp (91.7%) 
LoF 0.1% 0.1% LoF 10,729 
Common 
(0.1% MAF) 
0.1% 0.1% 
LoF 
inframe insertions or deletions 
PolyPhen-2 (HumDiv) “probably” damaging 
17,108 
Presumed 
Neutral 
0.05% 0% Synonymous substitution 14,956 
Table 1. Qualifying variant criteria in the four models. 528 
^Primary analysis permits minor allele frequency (MAF) to be up to 0.05% (i.e., up to four alleles in the combined case and control test population) to accommodate for possible 529 
recurrent pathogenic variants that might be relevant to multiple cases. GGE = genetic generalized epilepsy. NAFE = non-acquired focal epilepsy. LoF = loss-of-function. MAF 530 
= minor allele frequency. CCDS = consensus coding sequence 531 
 532 
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Group Gene set 
Number 
of genes 
Average 
qualifying 
variants
a
 
Qualifying variants 
enrichment p-value  
(Odds Ratio [95% CI]) 
Neutral 
variation 
enrichment 
p-value 
Enrichment after 
removing the 43 
epilepsy genes 
p-value 
Familial 
GGE  
Known 43 0.052 
p = 9.1x10
-8  
(OR=2.3 [95% CI 1.7 - 3.2]) 
p = 0.86 N/A 
Known 
(EE) 
33 0.037 
p = 2.6x10
-7
  
(OR=2.6 [95% CI 1.8 - 3.6]) 
p = 0.34 N/A 
Ion 
Channel 
209 0.264 
p = 0.028
 
(OR=1.2 [95% CI 1.0 - 1.5]) 
p = 0.73 p = 0.21 
FMRP 823 1.481 
p = 0.034
 
(OR=1.3 [95% CI 1.0 - 1.6]) 
p = 0.94 p = 0.04 
NMDAR 
& ARC 
78 0.067 
p = 0.004
 
(OR=1.6 [95% CI 1.1 - 2.1]) 
p = 0.80 p = 0.007 
MGI 
Seizure 
235 0.269 
p = 0.003
 
(OR=1.3 [95% CI 1.1 - 1.6]) 
p = 0.97 p = 0.17 
Familial 
NAFE  
Known 43 0.055 
p = 1.1x10
-17 
(OR=3.6 [95% CI 2.7 - 4.9]) 
p = 0.87 N/A 
Known 
(EE) 
33 0.037 
p = 5.0x10
-11
 
(OR=3.3 [95% CI 2.3 - 4.7]) 
p = 0.65 N/A 
Ion 
Channel 
209 0.264 
p = 1.9x10
-4 
(OR=1.5 [95% CI 1.2 - 1.8]) 
p = 0.47 p = 0.05 
FMRP 823 1.466 
p = 0.77 
(OR=1.0 [95% CI 0.8 - 1.2]) 
p = 0.77 p = 0.38 
NMDAR 
& ARC 
78 0.061 
p = 0.43
 
(OR=0.8 [95% CI 0.5 - 1.3]) 
p = 0.62 p = 0.40 
MGI 
Seizure 
235 0.261 
p = 0.05
 
(OR=1.2 [95% CI 1.0 - 1.5]) 
p = 0.81 p = 0.87 
Sporadic 
NAFE 
Known 43 0.045 
p = 0.27 
(OR=1.2 [95% CI 0.8 - 1.8]) 
p = 0.27 N/A 
Known 
(EE) 
33 0.030 
p = 0.79 
(OR=0.9 [95% CI 0.5 - 1.5]) 
p = 0.49 N/A 
Ion 
Channel 
209 0.251 
p = 0.34 
(OR=0.9 [95% CI 0.7 - 1.1]) 
p = 0.88 p = 0.25 
FMRP 823 1.461 
p = 0.95 
(OR=1.0 [95% CI 0.8 - 1.2]) 
p = 0.92 p = 0.94 
NMDAR 
& ARC 
78 0.063 
p = 0.65 
(OR=1.1 [95% CI 0.8 - 1.5]) 
p = 0.49 p = 0.70 
MGI 
Seizure 
235 0.254 
p = 0.36 
(OR=0.9 [95% CI 0.7 - 1.1]) 
p = 0.33 p = 0.33 
Table 2. Gene-set enrichment tests. P-values are from a logistic regression model that regresses the 533 
case/control status of a sample on the presence (1) or absence (0) of at least one qualifying variant among the 534 
corresponding gene set (Primary model). Reported p-values are uncorrected; the study-wide multiplicity-535 
adjusted significance threshold α = 8.9x10
-7
. All tests use the individual’s gender, exome-wide tally of 536 
qualifying variants, and the individual’s gene-list-specific tally of rare neutral (synonymous) variation as 537 
correction factors (appendix). Known = 43 established dominant human epilepsy genes.
3
 Known (EE) = A 538 
subset of genes securely implicated with epileptic encephalopathies. Ion Channel = genes coding for ion 539 
26 
 
channels.
25
 FMRP = fragile X mental retardation protein  associated genes.
22
 NMDAR & ARC = NMDA 540 
receptor and neuronal activity-regulated cytoskeleton-associated protein synaptic transmission genes .
23
 MGI 541 
Seizure = mouse orthologs linked with seizure phenotypes in the Mouse Genome Database.
24
  
a
Average number 542 
of qualifying variants in the corresponding gene set, per sample in the test population.   543 
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Figure 1: Familial GGE primary model analysis. 15,515 genes had at least one case or control 544 
carrier (table 1). Qualifying variants were defined as a minor allele frequency <0.05% in internal case 545 
and control, and absent among external reference cohorts. Variants are annotated as loss-of-function, 546 
inframe insertions or deletions, or missense predicted to be “probably damaging” by PolyPhen-2 547 
(HumDiv). No gene achieved study-wide significance (adjusted α < 0.05/[18668 * 3] = 8.9x10-7). 548 
549 
  550 
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Figure 2: Familial NAFE primary model analysis. (A) 15,438 genes had at least one case or control carrier (table 1). Qualifying variants have a minor allele 551 
frequency <0.05% in internal case and control, and are absent among external reference cohorts. Variants are annotated as loss-of-function, inframe insertions or 552 
deletions, or missense predicted to be “probably damaging” by PolyPhen-2 (HumDiv). Only DEPDC5, achieved study-wide significance (adjusted α < 553 
0.05/[18668 * 3] = 8.9x10
-7
). (B) 10,601 genes had at least one case or control carrier (table 1). Qualifying variants are variants with a population MAF<0.1% and 554 
annotated as loss-of-function effects. Only DEPDC5 achieved study-wide significance.    555 
 556 
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Figure 3: Enrichment of qualifying variants among 43 known epilepsy genes across increasing 557 
minor allele frequency bins. The ultra-rare variation bin reflects qualifying variants from the 558 
primary analyses. The 0.005% MAF (conditional) bin represents qualifying variants with a MAF 559 
greater than 0% but no greater than 0.005% in ExAC. The 0.1% MAF (conditional) bin represents 560 
qualifying variants with a MAF greater than 0.005% but no greater than 0.1% in ExAC. The neutral 561 
(synonymous)bin represents ultra-rare putatively neutral variants across the 43 epilepsy genes. 562 
Multivariate conditional analyses for the (A) familial GGE population (B) familial NAFE population 563 
(C) sporadic NAFE 564 
 565 
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